A Phase 2 Clinical Trial of Combination Nivolumab, Ipilimumab, and Paclitaxel in Patients With Untreated Metastatic NSCLC: The OPTIMAL Trial

A Phase 2 Clinical Trial of Combination Nivolumab, Ipilimumab, and Paclitaxel in Patients With Untreated Metastatic NSCLC: The OPTIMAL Trial

Introduction: Most patients with advanced NSCLC will experience disease progression and death within 2 years. Novel approaches are needed to improve outcomes. Methods: We conducted an open-label, nonrandomized, phase 2 trial in patients with treatment-naive, advanced NSCLC to assess the safety and e...

Full description

Bibliographic Details
Main Authors: Jeffrey M. Clarke, MD, Lin Gu, MS, Xiaofei F. Wang, PhD, Thomas E. Stinchcombe, MD, Marvaretta M. Stevenson, MD, Sundhar Ramalingam, MD, Afreen Shariff, MD, Jennifer Garst, MD, Andrew B. Nixon, PhD, Scott J. Antonia, MD, Jeffrey Crawford, MD, Neal E. Ready, MD, PhD
Format: Article
Language:English
Published: Elsevier 2022-06-01
Series:JTO Clinical and Research Reports
Subjects:
Non–small cell lung cancer
Immunotherapy
Nivolumab
Ipilimumab
Chemotherapy
Clinical trial
Online Access:http://www.sciencedirect.com/science/article/pii/S2666364322000613

Internet

http://www.sciencedirect.com/science/article/pii/S2666364322000613

Similar Items